心力衰竭的性别差异与减少的射出分数在银河系-HF试验中的性差异
Maria Pabon1, Jon Cunningham1, Brian Claggett1
1Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
JACC. Heart failure
|October 13, 2023
概括
患有心力衰竭和减少喷射分数 (HFrEF) 的妇女的生活质量较差,但不良事件的风险较低. 奥梅卡姆蒂夫 (omecamtiv mecarbil) 的疗效和安全性在患有HFrEF的男性和女性中都相似.
科学领域:
- 心脏病学 心脏病学
- 临床试验 临床试验
- 医学中的性别差异.
背景情况:
- 患有心力衰竭的女性减少射出分数 (HFrEF) 通常接受低于最佳的指导方针推的治疗,并报告生活质量低于男性.
- 现有研究表明,对于患有HFrEF的女性来说,治疗和结果可能存在差异.
研究的目的:
- 调查基线特征,临床结果以及omecamtiv mecarbil的疗效和安全性的基于性别的差异.
- 在GALACTIC-HF研究中分析omecamtiv mecarbil的治疗效果在男性和女性之间如何变化.
主要方法:
- 在GALACTIC-HF研究中,随机选择了具有症状HFrEF (EF ≤ 35%) 的患者接受omecamtiv mecarbil或安慰剂.
- 这项分析特别比较了男性和女性参与者之间的omecamtiv mecarbil的基线特征,临床结果和治疗效果.
主要成果:
- 在8,232名分析患者中,女性占21.2%,在基线时出现了更严重的症状 (较低的KCCQ-TSS) 和较少的基于指南的治疗.
- 尽管有基线差异,但与男性相比,女性的初级复合终点 (心血管死亡,心力衰竭事件或全因死亡) 风险比男性低20%.
- 奥梅卡姆提夫 (omecamtiv) 的治疗效果在两性之间一致,没有显著的相互作用 (P=0.68),女性报告的严重不良事件较少.
结论:
- 参与GALACTIC-HF试验的女性生活质量较差,接受的指导方针治疗较少,但患主要心血管不良事件的风险较低.
- 在男性和女性之间,omecamtiv mecarbil的疗效和安全性是可比的,这表明它的益处并不取决于性别.
- 这些发现强调了在HFrEF管理中解决性别差异的重要性,同时证实了omecamtiv mecarbil在不同患者群体中的潜在作用.
相关概念视频
01:30Heart Failure V: Medical Management
10
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
10
01:29Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
01:26Heart Failure III: Clinical Manifestations
22
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
22
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:30Heart Failure IV: Classification and Diagnostic Evaluation
19
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
19
01:22Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346